Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2012 Jul 2;122(7):2702. doi: 10.1172/JCI64256

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Cynthia X Ma, Shirong Cai, Shunqiang Li, Christine E Ryan, Zhanfang Guo, W Timothy Schaiff, Li Lin, Jeremy Hoog, Reece J Goiffon, Aleix Prat, Rebecca L Aft, Matthew J Ellis, Helen Piwnica-Worms
PMCID: PMC3386838

Original citation: J. Clin. Invest. 2012;122(4):1541–1552. doi:10.1172/JCI58765.

Citation for this erratum: J. Clin. Invest. 2012;122(7):2702. doi:10.1172/JCI64256.

The phrase “results in apoptosis” was inadvertently omitted from the fourth sentence of the abstract. The correct sentence appears below.

Previous studies have shown that inhibition of Chk1 in a p53-deficient background results in apoptosis in response to DNA damage.

The JCI regrets the error.


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES